Clotiapine
Clotiapine (Entumine) is an atypical antipsychotic[1] of the dibenzothiazepine chemical class.[2] It was first introduced in a few European countries (namely, Belgium, Italy, Spain and Switzerland), Argentina, Taiwan and Israel in 1970.[3]
Clinical data | |
---|---|
Trade names | Etumina, Etumine, Entumin, Etomine, Entumine |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, Intravenous and Intramuscular |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.016.512 |
Chemical and physical data | |
Formula | C18H18ClN3S |
Molar mass | 343.87 g·mol−1 |
3D model (JSmol) | |
SMILES
| |
InChI
| |
NY (what is this?) (verify) |
Some sources regard clotiapine as a typical antipsychotic rather than atypical due to its high incidence of extrapyramidal side effects compared to the atypicals like clozapine and quetiapine, to which it is structurally related.[4] Despite its profile of a relatively high incidence of extrapyramidal side effects it has demonstrated efficacy in treatment-resistant individuals with schizophrenia according to a number of psychiatrists with clinical experience with it, some weak clinical evidence supports this view too.[3][4][5] A systematic review compared clotiapine with other antipsychotic drugs:
Summary | ||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
There was no evidence to support or refute the use of clotiapine in preference to other antipsychotic drug treatments for management of people with acute psychotic illness.[6] | ||||||||||||||||||||||||||||||||||||||||
|
References
- Seminara G, Trassari V, Prestifilippo N, Chiavetta R, Calandra C (June 1993). "[Atypical tricyclic neuroleptics for treatment of schizophrenia. Clothiapine and clozapine]". Minerva Psichiatrica. 34 (2): 95–9. PMID 8105359.
- Schmutz J, Künzle F, Hunziker F, Gauch R (1967). "Über in 11-Stellung amino-substituierte Dibenzo[b,f]-1, 4-thiazepine und -oxazepine. 9. Mitteilung über siebengliedrige Heterocyclen". Helvetica Chimica Acta. 50: 245–254. doi:10.1002/hlca.19670500131.
- Lokshin, P; Kotler, M; Belmaker, RH (September 1997). "Clotiapine: Another forgotten treasure in psychiatry?". European Neuropsychopharmacology. 7 (Suppl 2): S217. doi:10.1016/S0924-977X(97)88712-3.
- Geller V, Gorzaltsan I, Shleifer T, Belmaker RH, Bersudsky Y (December 2005). "Clotiapine compared with chlorpromazine in chronic schizophrenia". Schizophrenia Research. 80 (2–3): 343–7. doi:10.1016/j.schres.2005.07.007. PMID 16126373.
- Van Wyk AJ, Marais GF (August 1971). "Chlorpromazine, clotiapine and thioridazine--a comparative clinical trial on Bantu psychotic patients" (PDF). South African Medical Journal = Suid-Afrikaanse Tydskrif vir Geneeskunde. 45 (34): 945–7. PMID 4939661.
- Carpenter S, Berk M, Rathbone J (October 2004). "Clotiapine for acute psychotic illnesses". The Cochrane Database of Systematic Reviews. 4 (4): CD002304. doi:10.1002/14651858.CD002304.pub2. PMID 15495032.
Typical |
|
---|---|
Disputed | |
Atypical |
|
Others |
|
|
Classes |
|
---|---|
Antidepressants (TCAs and TeCAs) |
|
Antihistamines |
|
Antipsychotics |
|
Anticonvulsants | |
Others |
|